<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056572</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-B3139-II-01</org_study_id>
    <nct_id>NCT04056572</nct_id>
  </id_info>
  <brief_title>Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib</brief_title>
  <official_title>A Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of TQ-B3139 in Patients With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of TQ-B3139 in subjects with ALK-positive non-small cell
      lung cancer that have demonstrated progression during or after crizotinib treatment whether
      or not previously treated with cytotoxic chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>The percentage of participants with a best overall response defined as complete response (CR) or partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>The time from randomization to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Calculated as the percentage of participants with best overall response of CR, PR, stable disease (SD) and Non-CR/Non-progressive disease (PD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Time from date of randomization to date of death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>ALK-positive NSCLC</condition>
  <arm_group>
    <arm_group_label>TQ-B3139</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQ-B3139 tablet 600mg administered orally, twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-B3139</intervention_name>
    <description>TQ-B3139 is competitive multi-target protein kinase inhibitor of Met/ALK/ROS.</description>
    <arm_group_label>TQ-B3139</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 and 75 years.

          2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.

          3. Life expectancy ≥12 weeks.

          4. Histologically or cytologically confirmed diagnosis of advanced or metastatic NSCLC
             that is ALK-positive.

          5. Has progressive disease during or after crizotinib treatment.

          6. Has a measurable disease.

          7. Adequate organ system function.

          8. Understood and signed an informed consent form.

        Exclusion Criteria:

          1. Diagnosed and/or treated additional malignancy within 5 years prior to randomization.

          2. Hypersensitivity to TQ-B3139 capsule.

          3. Has received ALK TKIs other than crizotinib.

          4. Has received any cancer therapy within 4 weeks or 5 times of t1/2.

          5. Has received major surgery within 4 weeks.

          6. Has received any radiotherapy or minor surgery within 2 weeks.

          7. Acute toxicity ≥ Grade 2 caused by previous cancer therapy.

          8. Has active viral, bacterial and fungal infections within 2 weeks.

          9. Has serious cardiovascular diseases.

         10. Has currently uncontrollable congestive heart failure.

         11. Has continuous arrhythmia ≥ Grade 2, any degree of poor controlled atrial fibrillation
             or QTc interval &gt; 480ms.

         12. Has interstitial fibrosis or interstitial lung disease.

         13. Brain metastases with symptom or carcinomatous meningitis.

         14. Has active hepatitis B or hepatitis C.

         15. Has multiple factors affecting oral medication.

         16. Breastfeeding or pregnant women.

         17. According to the judgement of the researchers, there are other factors that subjects
             are not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Zhang, Doctor</last_name>
    <phone>020-87343088</phone>
    <email>zhangli@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun-Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang, Doctor</last_name>
      <phone>020-87343088</phone>
      <email>zhangli@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Li zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nong Yang, Doctor</last_name>
      <phone>+86-731-88651900</phone>
      <email>yangnong0217@163.com</email>
    </contact>
    <investigator>
      <last_name>Nong Yang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

